Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1 biEBOV in healthy Tanzanian volunteers
NCT05301504Phase 1Unknown
- Sponsor
- University of Oxford
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAdOx1 biEBOV in Ebola virus disease (EVD) and Sudan virus disease (SVD) (4 arms), sponsored by University of Oxford. Primary endpoint: Safety and tolerability of ChAdOx1 biEBOV at 6 months. Status: unknown.
02
Drugs
ChAdOx1 biEBOV
03
Conditions
Ebola virus disease (EVD)Sudan virus disease (SVD)
Beyond the preview
Go deeper on NCT05301504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05301504.